Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10087
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company’s pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin activator in Phase 3 for heart failure; and reldesemtiv, a next-generation fast skeletal muscle troponin activator in Phase 2 for the treatment of spinal muscular atrophy; chronic obstructive pulmonary disease; and in Phase 1b for frailty. It is also investigating reldesemtiv for amyotrophic lateral sclerosis. It has licensing agreements with Amgen and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Cytokinetics Inc (CYTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Equity Offering 15
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc – Key Competitors 26
Cytokinetics Inc – Key Employees 27
Cytokinetics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: Cytokinetics reports third quarter 2018 financial results 29
Jul 26, 2018: Cytokinetics Reports Second Quarter 2018 Financial Results 31
Apr 26, 2018: Cytokinetics Reports First Quarter 2018 Financial Results 34
Feb 15, 2018: Cytokinetics Reports Fourth Quarter 2017 Financial Results 36
Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 38
Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 40
Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 42
Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 47
Feb 12, 2018: Cytokinetics Appoints Robert Califf, M.D., to Board of Directors 47
Product News 48
Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 48
Product Approvals 49
May 15, 2017: Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy 49
Clinical Trials 50
Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference 50
Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 51
Jan 03, 2018: Cytokinetics Provides on CK-2127107 52
Dec 11, 2017: Cytokinetics Publishes Clinical Trial Data for CK-2127107 53
Nov 30, 2017: New Publication Summarizes Phase 1 Studies Of CK-2127107 Showing Tolerability And Amplification Of Skeletal Muscle Response To Nerve Activation 54
Jul 27, 2017: Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis 56
Jul 05, 2017: Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA 57
Mar 29, 2017: Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy 59
Mar 22, 2017: Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc, Key Competitors 26
Cytokinetics Inc, Key Employees 27

List of Figures
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • St. Joseph Health:企業の戦略的SWOT分析
    St. Joseph Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • SugarBud Craft Growers Corp (RRL):企業の財務・戦略的SWOT分析
    Summary SugarBud Craft Growers Corp, (SugarBud) formerly New Range Resources Ltd is an oil and gas company that offers oil and gas exploration and development services. The company acquires, explores, operates, manages, produces, and develops crude oil and natural gas in Alberta and Saskatchewan. It …
  • Tenet Healthcare Corp (THC):企業の財務・戦略的SWOT分析
    Tenet Healthcare Corp (THC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Aitken Spence Hotel Holdings PLC:企業の戦略・SWOT・財務情報
    Aitken Spence Hotel Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary Aitken Spence Hotel Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Rosoboronexport:戦略・SWOT・企業財務分析
    Rosoboronexport - Strategy, SWOT and Corporate Finance Report Summary Rosoboronexport - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • HemaCare Corp (HEMA)-医療機器分野:企業M&A・提携分析
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, bone marrow and cord blood. It spans its expertise in isolations, custom cell collections and testing of pr …
  • Britannia Industries Ltd (BRITANNIA):企業の財務・戦略的SWOT分析
    Britannia Industries Ltd (BRITANNIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Chinook Energy Inc (CKE):石油・ガス:M&Aディール及び事業提携情報
    Summary Chinook Energy Inc (Chinook) is an oil and gas company that offers exploration, development and production of oil and gas properties in Western Canada. The company explores and develops crude oil, natural gas liquids and natural gas. It develops inventory from the BBT Concession, exploration …
  • South Egypt Drug Industries Co:企業の戦略的SWOT分析
    South Egypt Drug Industries Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Suncorp Group Ltd:企業の戦略・SWOT・財務情報
    Suncorp Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Suncorp Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • LT Group, Inc. (LTG):企業の財務・戦略的SWOT分析
    LT Group, Inc. (LTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SIFCO Industries, Inc.:戦略・SWOT・企業財務分析
    SIFCO Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary SIFCO Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • American Woodmark Corp (AMWD):企業の財務・戦略的SWOT分析
    American Woodmark Corp (AMWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Chromatin Inc:企業のM&A・事業提携・投資動向
    Chromatin Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chromatin Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Finning International Inc. (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc. (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • ITV plc:企業の戦略・SWOT・財務分析
    ITV plc - Strategy, SWOT and Corporate Finance Report Summary ITV plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • LifeNet Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary LifeNet Health Inc (LifeNet Health) is a non-profit organization that specializes in regenerative medicine. It offers allograft bio-implants and organs for transplantation. The organization specializes in offering organ procurement, tissue banking and transplant services. It provides allogra …
  • Riot Blockchain Inc (RIOT):企業の財務・戦略的SWOT分析
    Riot Blockchain Inc (RIOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Medical Research Council-製薬・医療分野:企業M&A・提携分析
    Summary Medical Research Council (MRC) is a human health research council that offers medical research programs. The council offers research across medical sciences services, universities and hospitals, centers and institutes. It provides data management, research platform, tools and facilities to g …
  • Neusoft Medical Systems Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Neusoft Medical Systems Co Ltd (Neusoft Medical), a subsidiary of Neusoft Corp is a medical device company that provides medical equipment and services. The company offers medical imaging equipment, e-hospital solutions, regional medical and personal healthcare products. Its product portfoli …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆